AYTU BIOPHARMA, INC — Form 8-K
Filed September 22, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 28/100
What the filing says
Aytu reported FY2026 net revenue of $57.6M (down 13.3% YoY from $66.4M), with new product EXXUA generating $6.6M in its first year of sales ($3.9M in Q4 alone, up 63% sequentially). Legacy ADHD portfolio fell to $45.8M from $57.6M due to commercial deprioritization and generic competition; Pediatric portfolio declined to $5.1M from $8.8M. Net loss was $14.3M (vs. $13.6M prior year); Adjusted EBITDA turned negative at ($3.7M) from $9.2M. Cash position fell to $26.3M from $31.0M. Company emphasized EXXUA momentum (3,323 Q4 prescriptions, +138% QoQ) and cash generation from legacy products.
Why this rating
EXXUA shows strong traction but legacy revenue collapse and negative Adj. EBITDA outweigh early gains. At $7.2M market cap, $14M loss and declining cash burn are material; however, $26M cash runway and profitable legacy base limit immediate distress risk.
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.